Difference between revisions of "Alcuronium chloride"
m (activated IUPHAR link) |
m (1 revision: World Health Organization essential medicines) |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 42: | Line 42: | ||
== References == | == References == | ||
{{cite journal | author = Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K | title = Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. | journal = J Pharmacol Exp Ther | volume = 301 | issue = 2 | pages = 720–8 | year = 2002 | pmid = 11961078 | doi = 10.1124/jpet.301.2.720}} | {{cite journal | author = Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K | title = Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. | journal = J Pharmacol Exp Ther | volume = 301 | issue = 2 | pages = 720–8 | year = 2002 | pmid = 11961078 | doi = 10.1124/jpet.301.2.720}} | ||
+ | |||
{{cite journal | author = Maass A, Mohr K | title = Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors. | journal = Eur J Pharmacol | volume = 305 | issue = 1-3 | pages = 231–4 | year = 1996 | pmid = 8813558 | doi = 10.1016/0014-2999(96)00240-3}} | {{cite journal | author = Maass A, Mohr K | title = Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors. | journal = Eur J Pharmacol | volume = 305 | issue = 1-3 | pages = 231–4 | year = 1996 | pmid = 8813558 | doi = 10.1016/0014-2999(96)00240-3}} | ||
− | {{cite journal | author = Jakubík J, Tucek S | title = Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium. | journal = J Neurochem | volume = 63 | issue = 5 | pages = 1932–40 | year = 1994 | pmid = 7931349}} | + | |
+ | {{cite journal | doi = 10.1046/j.1471-4159.1994.63051932.x | author = Jakubík J, Tucek S | title = Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium. | journal = J Neurochem | volume = 63 | issue = 5 | pages = 1932–40 | year = 1994 | pmid = 7931349}} | ||
+ | |||
{{cite journal | author = Proska J, Tucek S | title = Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. | journal = Mol Pharmacol | volume = 45 | issue = 4 | pages = 709–17 | year = 1994 | pmid = 8183250}} | {{cite journal | author = Proska J, Tucek S | title = Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. | journal = Mol Pharmacol | volume = 45 | issue = 4 | pages = 709–17 | year = 1994 | pmid = 8183250}} | ||
Line 50: | Line 53: | ||
− | |||
[[Category:Muscle relaxants]] | [[Category:Muscle relaxants]] | ||
[[Category:World Health Organization essential medicines]] | [[Category:World Health Organization essential medicines]] | ||
+ | |||
+ | |||
+ | {{musculoskeletal-drug-stub}} | ||
[[de:Alcuroniumchlorid]] | [[de:Alcuroniumchlorid]] |
Latest revision as of 16:48, 27 September 2010
File:Alcuroniumchlorid.svg | |
File:Alcuronium3d.png | |
Systematic (IUPAC) name | |
---|---|
4,4'-Didemethyl-4,4'-di-propenyltoxiferin-1-dichloride | |
Pharmacokinetic data | |
Metabolism | not metabolized |
Excretion | 70-90% unchanged in urine 1.3ml/kg/min t1/2 2- 4 hours |
Identifiers | |
CAS Number | 23214-96-2 |
ATC code | M03AA01 (WHO) |
PubChem | CID 5311001 |
IUPHAR/BPS | 341 |
ChemSpider | 20118193 |
Chemical data | |
Formula | C44H50N4O2Script error: No such module "String". |
Molar mass | 666.894 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Alcuronium is a peripherally acting muscle relaxant in the curare alkaloid family. It is a semi-synthetic substance derived from toxiferine.
Effects
- Cardiovascular system - histamine release and blockage of the sympathetic ganglia including adrenal medulla could cause Hypotension
- Respiratory - apnea due to phrenic blockage but bronchoconstriction can occur from the histamine release
- Central nervous system - no effect on intraoccular pressure
- Autonomic ganglion blockade can cause decrease in gut motility
Special points
- Duration of action prolonger in states of low potassium, calcium and protein, also in states of high magnesium and acidosis.
- Pharmaceutically incompatible with thiopentone
- Infusion can cause fixed dilated pupils
References
Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K (2002). "Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist". J Pharmacol Exp Ther. 301 (2): 720–8. doi:10.1124/jpet.301.2.720. PMID 11961078.
Maass A, Mohr K (1996). "Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors". Eur J Pharmacol. 305 (1-3): 231–4. doi:10.1016/0014-2999(96)00240-3. PMID 8813558.
Jakubík J, Tucek S (1994). "Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium". J Neurochem. 63 (5): 1932–40. doi:10.1046/j.1471-4159.1994.63051932.x. PMID 7931349.
Proska J, Tucek S (1994). "Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors". Mol Pharmacol. 45 (4): 709–17. PMID 8183250.
45px | This drug article relating to the musculoskeletal system is a stub. You can help ssf by expanding it. |
- Pages with script errors
- Pages using duplicate arguments in template calls
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Multiple names: authors list
- 2Fix
- Muscle relaxants
- World Health Organization essential medicines
- Musculoskeletal system drug stubs